IMVT

Healthcare Biotechnology

Immunovant, Inc.

$33.62

-0.03 -0.09% today

Price History

Not enough data

Key Stats

Market Cap

6.94B

Avg Volume

1.23M

EPS

-$2.81

52W High

$45.42

52W Low

$15.95

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-12.22

P/B Ratio

9.43

EV/EBITDA

-10.87

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(80.1%)

Return on Assets

(46.7%)

Liquidity & Leverage

Current Ratio

7.27

Quick Ratio

6.82

Total Cash

797.80M

Total Debt

About

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

immunovant.com